Peer-reviewed article
EFFECTIVENESS AND SAFETY OF CYD-TDV VACCINE IN CHILDREN
Sonny Edbert, Hotimah Masdan Salim ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This systematic review and meta-analysis examined the effectiveness and safety of the CYD-TDV dengue vaccine in children living in dengue-endemic areas, particularly Indonesia. The analysis included studies published between 2017 and 2020 from medical databases. The vaccine showed higher immunogenicity (immune response) in vaccinated children compared to control groups, with no significant difference in side effects between the groups. The authors conclude that CYD-TDV is both effective and safe for children in endemic regions.
Key points
- CYD-TDV is the only commercially available dengue vaccine, licensed by Sanofi Pasteur
- Immunogenicity was significantly higher in vaccinated children than in control groups
- Side effects between vaccinated and control groups were not significant
- Dengue virus incidence continues to grow in children, particularly in Asia
- Vaccine development should be prioritized for Asian regions including Indonesia
Limitations
The document does not provide specific immunogenicity values, side effect rates, or detailed methodological quality assessment of included studies. It does not discuss long-term effectiveness, protection duration, or real-world effectiveness outside controlled trial settings.
Abstract
Dengue virus is classified as an arbovirus and its incidence rate continues to grow, especially in children in the last few years recorded by WHO. In the absence of specific therapy to treat dengue, prevention with vaccination is the right choice, especially for Asia and endemic regions such as Indonesia. Until now, the vaccine for dengue is only available in one commercial formulation (CYD-TDV) which has been licensed and developed by Sanofi Pasteur. The purpose of this study is to determine the effectiveness and safety of the CYD-TDV vaccine for children in endemic areas. The method used in this study is a literature search. Conducted meta-analyses and systematic reviews published between 2017 and 2020 identified in MEDLINE, especially in children based on inclusion and exclusion criteria. The findings obtained are Immunogenicity in the test group vaccinated with CYD-TDV was higher than the control group and side effects between two groups were not significant. So it can be concluded CYD-TDV vaccine is effective and safe for children’s in endemic areas. This conclusion is the basis for further vaccine development, especially for Asian regions, such as Indonesia.
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- CYD-TDV dengue vaccine administration to children
- Population
- Children in dengue-endemic areas
Key finding
Immunogenicity in vaccinated group was higher than control group